Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic... by Hoffmann, L., Persson, G.F., Nygård, L., Nielsen, T.B., Borrisova, S., Gaard-Petersen, F., Josipovic, M., Khalil, A.A., Kjeldsen, R., Knap, M.M., Kristiansen, C., Møller, D.S., Ottosson, W., Sand, H., Thing, R., Pøhl, M., Schytte, T.

Get full text

PO-1706 Stereotactic body radiotherapy for bone metastases: Initial lessons learned regarding setup by Gaard-Petersen, F., van Overeem Felter, M., Josipovic, M., Serup-Hansen, E., Behrens, C.F., Persson, G.

Get full text

MO-0550 Pre-study QA reduces delineation errors and minimize dose to OAR in a central lung tumour SBRT trial by Hoffmann, L., Persson, G.F., Nygård, L., Nielsen, T.B., Borrisova, S., Gaard-Petersen, F., Josipovic, M., Khalil, A.A., Kjeldsen, R., Knap, M.M., Kristiansen, C., Møller, D.S., Ottosson, W., Sand, H., Thing, R., Pøhl, M., Schytte, T.

Get full text

OC-0604 Early toxicity after SABR of oligometastatic bony metastases in the BONY M phase II trial by Spindler, N.J., Felter, M.V.O., Hansen, O., Nielsen, T.B., Suppli, M.H., Josipovic, M., Poulsen, L.Ø., Gaard-Petersen, F., Sand, H.M.B., Abramova, T.M., Johansen, M., Kornerup, J.S., Alsaker, M.D., Serup-Hansen, E., Geertsen, P., Vogelius, I.R., Behrens, C., Persson, G.F.

Get full text

3017: SABR of bony oligometastases, 1-year, efficacy, and toxicity analyses from the Bony-M trial by Spindler, Nicklas J., Felter, Mette v O, Hansen, Olfred, Nielsen, Tine B., Suppli, Morten H., Josipovic, Mirjana, Poulsen, Laurids Ø, Gaard-Petersen, Fatma, Andersen, Michael B., Sand, Hella M B, Johansen, Marie, Madsen, Kasper, Kornerup, Josefine S., Alsaker, Mirjam D., Serup-Hansen, Eva, Eefsen, Rikke L., Vogelius, Ivan R., Geertsen, Poul, Behrens, Claus P., Persson, Gitte F.

Get full text